Phylogica enters into Research and Licensing Agreement with Genentech
Advertisement
Phylogica Ltd announced that it has extended its collaboration with Genentech by entering into a Research and Licensing agreement to discover novel antibiotics. Phylogica will employ its Phylome® drug discovery platform, including its proprietary cellpenetrating peptide discovery technology to identify Phylomer peptides suitable for further evaluation.
Under the terms of the agreement, Phylogica will receive an upfront payment of US$500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US$142 million.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
PBL awarded two US patents on RNAi
Amyotrophic_lateral_sclerosis
St._Jude_Children's_Research_Hospital_(Memphis,_Tennessee)
Alpha_motor_neuron
